Summary: Marijuana Moment reports on the decision from Michigan’s Marijuana Regulatory Agency (MRA) to award MAPS a $12,979,050 grant to fund a Phase 2 clinical trial of self-titrated high-THC cannabis against placebo for treatment of PTSD among Veterans. Funded by adult-use marijuana retail taxes in Michigan, the grant supports the “next step of a study researchers say is the first clinical trial of inhaled botanical marijuana for post-traumatic stress disorder (PTSD) and only the second to compare the safety and efficacy of cannabis against a placebo,” as outlined by Ben Adlin of Marijuana Moment.
Originally appearing here.
